Xeris Biopharma Holdings, Inc. Common Stock

XERSNASDAQUSD
7.57 USD
0.12 (1.61%)AT CLOSE (11:59 AM EDT)
7.68
0.11 (1.43%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
7.68
0.11 (1.43%)
🔴Market: CLOSED

Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $7.59 per share. Technical and fundamental signals converge bearishtechnicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (176.3%) and a bullish Golden Cross on the moving averages. On valuation, XERS trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 14, 2026.

Open?$7.60
High?$7.69
Low?$7.52
Prev. Close?$7.45
Volume?2.0M
Avg. Volume?1.7M
VWAP?$7.60
Rel. Volume?1.17x
Bid / Ask
Bid?$6.52 × 100
Ask?$8.90 × 100
Spread?$2.38
Midpoint?$7.71
Valuation & Ratios
Market Cap?1.4B
Shares Out?182.3M
Float?176.1M
Float %?96.6%
P/E Ratio?N/A
P/B Ratio?-139.54
EPS?-$0.09
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Employees
435
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2018-06-21
Address
1375 WEST FULTON STREET, SUITE 1300
CHICAGO, IL 60607
Phone: 844-445-5704
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-1/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
10
Momentum?
75
Short Sent.?
74
Piotroski F-Score?3/9Weak
Altman Z-Score?0.91Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?4.57%Low
Short Interest?8.0M
Days to Cover?5.5
Free Float176.1M
Avg Daily Volume1.5M
Settlement Date2026-08-31
Financial Health
Current Ratio?1.45Adequate
Quick Ratio?1.02Adequate
Cash Ratio?0.64Adequate
Debt/Equity?-25.95Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
S&P
97
-139.54CHEAP
P/S?
Peers
100
S&P
38
4.05FAIR
P/FCF?
Peers
100
S&P
41
24.4FAIR
EV/EBITDA?
Peers
100
S&P
10
30.5HIGH
EV/Sales?
Peers
100
S&P
41
4.44FAIR
Returns & Efficiency
ROE?
Peers
50
S&P
97
176.3%STRONG
ROA?
S&P
3
-4.2%WEAK
Cash Flow & Enterprise
FCF?$55.7M
Enterprise Value?$1.5B
Fundamentals ratios updated end of day